This comprehensive review explores the dynamic landscape of FDA-approved medications repurposed for COVID-19, highlighting diverse antiviral categories and emerging treatments like Molnupiravir.
This review provides a comprehensive overview of the historical evolution and latest developments in COVID-19 therapeutics, including repurposed medications and novel oral treatments.
Amidst the ongoing global challenge of the SARS-CoV-2 pandemic, the quest for effective antiviral medications remains paramount. This comprehensive review delves into the dynamic landscape of FDA-approved medications repurposed for COVID-19, categorized as antiviral and non-antiviral agents. Our focus extends beyond conventional narratives, encompassing vaccination targets, repurposing efficacy, clinical studies, innovative treatment modalities, and future outlooks. Unveiling the genomic intricacies of SARS-CoV-2 variants, including the WHO-designated Omicron variant, we explore diverse antiviral categories such as fusion inhibitors, protease inhibitors, transcription inhibitors, neuraminidase inhibitors, nucleoside reverse transcriptase, and non-antiviral interventions like importin α/β1-mediated nuclear import inhibitors, neutralizing antibodies, and convalescent plasma. Notably, Molnupiravir emerges as a pivotal player, now licensed in the UK. This review offers a fresh perspective on the historical evolution of COVID-19 therapeutics, from repurposing endeavors to the latest developments in oral anti-SARS-CoV-2 treatments, ushering in a new era of hope in the battle against the pandemic.
Barghash et al. (Mon,) conducted a review in COVID-19. COVID-19 therapeutics was evaluated. This comprehensive review explores the dynamic landscape of FDA-approved medications repurposed for COVID-19, highlighting diverse antiviral categories and emerging treatments like Molnupiravir.